Filing identity and reporting period
Important discrepancy: The request identifies Tuhura Biosciences, Inc., but the filing text is Kintara Therapeutics, Inc. (Nasdaq: KTRA). The 10-Q covers the quarter and six months ended December 31, 2022, for Kintara’s fiscal second quarter; it is not identified in the filing as a Tuhura filing. Financial amounts below are in U.S. dollars, generally thousands unless stated otherwise.
Business context
Kintara is a clinical-stage cancer drug developer with no revenue to date. Its principal programs are VAL-083, being studied for glioblastoma (GBM), and REM-001 for cutaneous metastatic breast cancer. The company paused REM-001 to conserve cash for VAL-083 development.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2022 | Six months ended Dec. 31, 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | None to date | None to date | None to date |
| Research and development expense | $2.059 million | $5.230 million | $3.902 million quarterly; $7.695 million six-month |
| General and administrative expense | $1.440 million | $2.915 million | $1.993 million quarterly; $4.171 million six-month |
| Net loss | $3.454 million | $8.050 million | $5.893 million quarterly; $11.859 million six-month |
| Loss per share | $2.10 | $5.42 | $6.07 quarterly; $17.30 six-month |
| Cash used in operating activities | Not separately stated | $8.530 million | $10.177 million six-month |
At December 31, 2022, cash and cash equivalents were $4.874 million, down from $11.780 million at June 30, 2022. Working capital was $5.939 million, total assets $9.917 million, total liabilities $3.319 million, and stockholders’ equity $6.598 million. The filing reports no revenue and does not provide a gross margin; margins are therefore not meaningful. No conventional borrowing or debt balance is identified in the provided filing text.
Six-month investing cash use was $232,000, primarily for equipment; financing provided $1.856 million net, including $1.860 million from Lincoln Park share sales. The company reported $1.700 million of additional clinical-trial deposits paid during the period. Its cash balance and six-month operating cash use underscore substantial financing needs.
Changes versus the prior comparable period
- Quarterly R&D expense fell 47% and G&A expense fell 28% year over year. Six-month R&D and G&A decreased 32% and 30%, respectively; management cited lower clinical costs, reduced staffing and lower share-based compensation, among other factors.
- Six-month net loss narrowed to $8.050 million from $11.859 million. Loss attributable to common stockholders also benefited from a lower Series C stock dividend: $362,000 versus $2.462 million in the prior-year period.
- Operating cash use declined to $8.530 million from $10.177 million, while financing proceeds dropped to $1.856 million from $13.704 million. Cash fell by $6.906 million during the six months.
- The company completed a 1-for-50 reverse stock split in November 2022. Share and per-share figures are retrospectively adjusted in the filing.
Outlook, risks and notable items
- Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern within one year from the filing date. Additional funding is required; management is pursuing equity, debt and/or strategic partnerships, with no assurance of success. Failure to obtain funding could lead to delays, reductions or termination of development programs.
- Capital and dilution: The August 2022 Lincoln Park agreement had a stated maximum commitment of $20 million, but sales had reached the current amount available under Nasdaq ownership limitations by December 31, 2022, generating about $1.860 million net. Further sales above the exchange cap require stockholder approval or satisfaction of the specified price condition. Future equity financing may dilute shareholders.
- Program prioritization: REM-001 was paused in October 2022; management expects this to save approximately $3.0 million through calendar 2023. The company is prioritizing the VAL-083 GBM AGILE study.
- Clinical outlook: Management estimated topline GBM AGILE results around the end of calendar 2023, described as 12 months after the last patient is randomized. The study remains ongoing, and clinical-trial success is uncertain. The filing says enrollment and treatment had not been significantly affected by COVID-19.
- Regulatory and corporate events: VAL-083 received FDA orphan drug designation for DIPG in December 2022. Nasdaq notified the company in November 2022 that it had regained compliance with the minimum bid-price requirement. REM-001 received FDA Fast Track designation, though its program is paused.
- Other disclosures: Series C preferred stock, warrants and options represent potential dilution. The company reported no legal proceedings, no material changes to previously disclosed risk factors, and effective disclosure controls; it reported no material internal-control changes during the quarter.
Important facts for investors to verify
- Confirm the issuer and period: the supplied filing is Kintara Therapeutics’ 10-Q for the quarter ended December 31, 2022, not a Tuhura Biosciences filing.
- Review subsequent financing, cash runway and the status of management’s going-concern plans; reported cash was $4.874 million against $8.530 million of six-month operating cash use.
- Check current status, enrollment and timing of the VAL-083 GBM AGILE study and whether the estimated topline timing changed.
- Verify whether REM-001 remains paused and whether the expected cost savings were achieved.
- Assess potential dilution from preferred shares, warrants, options and any additional equity financing.